drugset
drugset / Trial / NCT03578874

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

NCT03578874 ↗

Phase 2 Completed 15 enrolled The University of Hong Kong
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the resectability after treatment with SECOX (sorafenib, capecitabine, oxaliplatin) as neoadjuvant therapy in patients with locally advanced hepatocellular carcinoma

Timeline

Start
2016-06-20
Primary completion
2019-04-30
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 850 mg/m2 —
Subject Oxaliplatin Small molecule 85 mg/m2 —
Subject Sorafenib Small molecule 400 mg —

Indications

hepatocellular carcinoma